211 related articles for article (PubMed ID: 36853310)
1. Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals.
El-Kassas M; Sayed H; Omran D; Eldahrouty AH; Elbaz T; Kamal E
Asian Pac J Cancer Prev; 2023 Feb; 24(2):597-605. PubMed ID: 36853310
[TBL] [Abstract][Full Text] [Related]
2. ADAM10 Gene Polymorphism and Its Relationship to Hepatocellular Carcinoma in Egyptian HCV Patients Receiving Direct-Acting Antiviral Therapies (DAAs).
Ghanem S; El Gedawy G; Yehia S; Bedair H; Awad S; Abdel-Razek W; Elhelbawy M; El-Sabaawy D; Elfert AY
Asian Pac J Cancer Prev; 2023 Jan; 24(1):149-155. PubMed ID: 36708563
[TBL] [Abstract][Full Text] [Related]
3. De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial?
Montasser IF; Ibrahim AA; Farid HM; Al Balakosy AM
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101517. PubMed ID: 32900667
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
7. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
[TBL] [Abstract][Full Text] [Related]
8. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
9. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
10. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence.
Piñero F; Boin I; Chagas A; Quiñonez E; Marciano S; Vilatobá M; Santos L; Anders M; Hoyos Duque S; Soares Lima A; Menendez J; Padilla M; Poniachik J; Zapata R; Maraschio M; Chong Menéndez R; Muñoz L; Arufe D; Figueroa R; Mendizabal M; Hurtado Gomez S; Stucchi R; Maccali C; Vergara Sandoval R; Bermudez C; McCormack L; Varón A; Gadano A; Mattera J; Rubinstein F; Carrilho F; Silva M
Liver Transpl; 2020 May; 26(5):640-650. PubMed ID: 32133773
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan.
Chi CT; Chen CY; Su CW; Chen PY; Chu CJ; Lan KH; Lee IC; Hou MC; Huang YH
J Microbiol Immunol Infect; 2021 Jun; 54(3):385-395. PubMed ID: 31771822
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial.
Kamal A; Metawea M; Omar H; Ghallab M; Kassem A; Naguib H
J Gastrointest Cancer; 2024 Jun; 55(2):913-923. PubMed ID: 38436921
[TBL] [Abstract][Full Text] [Related]
13. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
14. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus.
Guardigni V; Toschi A; Badia L; Rosselli Del Turco E; Salsi E; Cristini F; Sighinolfi L; Fabbri G; Massari M; Cuomo G; Viale P; Verucchi G;
AIDS; 2021 Oct; 35(12):1967-1972. PubMed ID: 34101631
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
Reig M; Cabibbo G
J Hepatol; 2021 May; 74(5):1225-1233. PubMed ID: 33582128
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
[No Abstract] [Full Text] [Related]
18. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
[TBL] [Abstract][Full Text] [Related]
19. lnc-HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct-acting antivirals therapy.
El-Khazragy N; Elshimy AA; Hassan SS; Shaaban MH; Bayoumi AH; El Magdoub HM; Ghozy S; Gaballah A; Aboelhussein MM; Abou Gabal HH; Bannunah AM; Mansy AE
Mol Carcinog; 2020 Dec; 59(12):1382-1391. PubMed ID: 33074585
[TBL] [Abstract][Full Text] [Related]
20. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
